This blog is related to the various litigations related to patents w.r.t pharma industry.
Wednesday, November 25, 2009
LFB's Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in Europe for Chronic Lymphocytic Leukemia
Nov 25, 2009 - The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL).
No comments:
Post a Comment